CareDx, Inc (CDNA) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $17.63. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CDNA = $629.37 (+3469.9% from the current price, the stock appears undervalued). Analyst consensus target is CDNA = $23 (+32.3% upside).
Valuation: CDNA trades at a trailing Price-to-Earnings (P/E) of -40.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.08.
Financials: revenue is $380M, +6.7%/yr average growth. Net income is $21M (loss), growing at -53.8%/yr. Net profit margin is -5.6% (negative). Gross margin is 67% (+1.9 pp trend).
Balance sheet: total debt is $20M against $303M equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 2.86 (strong liquidity). Debt-to-assets is 4.8%. Total assets: $413M.
Analyst outlook: 10 / 13 analysts rate CDNA as buy (77%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 97/100 (Pass), Growth 40/100 (Partial), Past 25/100 (Fail), Health 100/100 (Pass), Moat 60/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).
